These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22940629)

  • 1. An essential role of MAG in mediating axon-myelin attachment in Charcot-Marie-Tooth 1A disease.
    Kinter J; Lazzati T; Schmid D; Zeis T; Erne B; Lützelschwab R; Steck AJ; Pareyson D; Peles E; Schaeren-Wiemers N
    Neurobiol Dis; 2013 Jan; 49():221-31. PubMed ID: 22940629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs.
    Hanemann CO; Gabreëls-Festen AA; Stoll G; Müller HW
    Acta Neuropathol; 1997 Oct; 94(4):310-5. PubMed ID: 9341930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies.
    Hanemann CO; Stoll G; D'Urso D; Fricke W; Martin JJ; Van Broeckhoven C; Mancardi GL; Bartke I; Müller HW
    J Neurosci Res; 1994 Apr; 37(5):654-9. PubMed ID: 8028042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCP-1/CCL2 modifies axon properties in a PMP22-overexpressing mouse model for Charcot-Marie-tooth 1A neuropathy.
    Kohl B; Fischer S; Groh J; Wessig C; Martini R
    Am J Pathol; 2010 Mar; 176(3):1390-9. PubMed ID: 20093502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice.
    Lee JS; Lee JY; Song DW; Bae HS; Doo HM; Yu HS; Lee KJ; Kim HK; Hwang H; Kwak G; Kim D; Kim S; Hong YB; Lee JM; Choi BO
    Nucleic Acids Res; 2020 Jan; 48(1):130-140. PubMed ID: 31713617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene dosage effects in hereditary peripheral neuropathy. Expression of peripheral myelin protein 22 in Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies nerve biopsies.
    Gabriel JM; Erne B; Pareyson D; Sghirlanzoni A; Taroni F; Steck AJ
    Neurology; 1997 Dec; 49(6):1635-40. PubMed ID: 9409359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexistence of Charcot Marie Tooth disease type 1A and diabetes in Taiwan: A clinicopathological study.
    Chao HC; Chou CT; Lee YC; Lin KP
    J Neurol Sci; 2015 Nov; 358(1-2):213-20. PubMed ID: 26349404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PMP22 expression in dermal nerve myelin from patients with CMT1A.
    Katona I; Wu X; Feely SM; Sottile S; Siskind CE; Miller LJ; Shy ME; Li J
    Brain; 2009 Jul; 132(Pt 7):1734-40. PubMed ID: 19447823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
    Chumakov I; Milet A; Cholet N; Primas G; Boucard A; Pereira Y; Graudens E; Mandel J; Laffaire J; Foucquier J; Glibert F; Bertrand V; Nave KA; Sereda MW; Vial E; Guedj M; Hajj R; Nabirotchkin S; Cohen D
    Orphanet J Rare Dis; 2014 Dec; 9():201. PubMed ID: 25491744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electroceutical approach ameliorates intracellular PMP22 aggregation and promotes pro-myelinating pathways in a CMT1A in vitro model.
    Intisar A; Woo H; Kang HG; Kim WH; Shin HY; Kim MY; Kim YS; Mo YJ; Lee YI; Kim MS
    Biosens Bioelectron; 2023 Mar; 224():115055. PubMed ID: 36630746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired expression of ciliary neurotrophic factor in Charcot-Marie-Tooth type 1A neuropathy.
    Nobbio L; Fiorese F; Vigo T; Cilli M; Gherardi G; Grandis M; Melcangi RC; Mancardi G; Abbruzzese M; Schenone A
    J Neuropathol Exp Neurol; 2009 May; 68(5):441-55. PubMed ID: 19525893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low affinity NGF receptor expression in CMT1A nerve biopsies of different disease stages.
    Hanemann CO; Gabreëls-Fasten AA; Müller HW; Stoll G
    Brain; 1996 Oct; 119 ( Pt 5)():1461-9. PubMed ID: 8931571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.
    Sociali G; Visigalli D; Prukop T; Cervellini I; Mannino E; Venturi C; Bruzzone S; Sereda MW; Schenone A
    Neurobiol Dis; 2016 Nov; 95():145-57. PubMed ID: 27431093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small axons relative to number of myelin lamellae in Charcot-Marie-Tooth disease 1A with peripheral myelin protein 22 gene duplication.
    Ohnishi A; Yamamoto T; Ikeda M
    J UOEH; 2000 Jun; 22(2):107-17. PubMed ID: 10862406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
    Prukop T; Stenzel J; Wernick S; Kungl T; Mroczek M; Adam J; Ewers D; Nabirotchkin S; Nave KA; Hajj R; Cohen D; Sereda MW
    PLoS One; 2019; 14(1):e0209752. PubMed ID: 30650121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new mouse model of Charcot-Marie-Tooth 2J neuropathy replicates human axonopathy and suggest alteration in axo-glia communication.
    Shackleford G; Marziali LN; Sasaki Y; Claessens A; Ferri C; Weinstock NI; Rossor AM; Silvestri NJ; Wilson ER; Hurley E; Kidd GJ; Manohar S; Ding D; Salvi RJ; Feltri ML; D'Antonio M; Wrabetz L
    PLoS Genet; 2022 Nov; 18(11):e1010477. PubMed ID: 36350884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice.
    Stavrou M; Kagiava A; Choudury SG; Jennings MJ; Wallace LM; Fowler AM; Heslegrave A; Richter J; Tryfonos C; Christodoulou C; Zetterberg H; Horvath R; Harper SQ; Kleopa KA
    J Clin Invest; 2022 Jul; 132(13):. PubMed ID: 35579942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARM1 knockout does not rescue neuromuscular phenotypes in a Charcot-Marie-Tooth disease Type 1A mouse model.
    Moss KR; Johnson AE; Bopp TS; Yu AT; Perry K; Chung T; Höke A
    J Peripher Nerv Syst; 2022 Mar; 27(1):58-66. PubMed ID: 35137510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelin and axon pathology in a long-term study of PMP22-overexpressing mice.
    Verhamme C; King RH; ten Asbroek AL; Muddle JR; Nourallah M; Wolterman R; Baas F; van Schaik IN
    J Neuropathol Exp Neurol; 2011 May; 70(5):386-98. PubMed ID: 21487305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients.
    Hattori N; Yamamoto M; Yoshihara T; Koike H; Nakagawa M; Yoshikawa H; Ohnishi A; Hayasaka K; Onodera O; Baba M; Yasuda H; Saito T; Nakashima K; Kira J; Kaji R; Oka N; Sobue G;
    Brain; 2003 Jan; 126(Pt 1):134-51. PubMed ID: 12477701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.